steel7610 (@steel7610)

Recently, the ECDC said that "Seven cases of toxigenic O1 Vibrio cholerae have been reported by two countries". Source: The ECDC's document titled "Communicable disease threats report, 1 - 7 March 2025, week 10" from March 7, 2025. Link: https://www.ecdc.europa.eu/en/publications-data/communicable-disease-threats-report-1-7-march-2025-week-10 Let's see what they said: Here are a few quotes from chapter "1. Cholera associated with holy well water from Ethiopia": Quote 1: "Seven cases of toxigenic O1 Vibrio cholerae have been reported by two countries; Germany (3) and UK (4). Four individuals had exposure to water from a holy well at Bermel Giorgis in the Amhara region of Ethiopia. Another two individuals had exposure to holy water from an unknown source in the Amhara region. The seventh individual had recently travelled to Ethiopia, but the region visited and exposures they had during their visit were not reported." Quote 2: "Germany reported three cases of toxigenic O1 Vibrio cholerae following exposure to water from a holy well at Bermel giorgis in Ethiopia. The water was brought to Germany in a plastic bottle by two of the individuals, but exposure occurred in Germany together with a third person, who had not travelled. Onset of the disease was in early February, four days after the exposure." Quote 3: "United Kingdom reports four adult cases of toxigenic O1 Vibrio cholerae diagnosed in mid February 2025. Three individuals reported recent travel to Ethiopia, two specifically to the Amhara region and of these, one had visited the holy well at Bermel Giorgis during their trip." Quote 4: "New cases may continue to occur until the source of contamination at the well has been addressed and protection of water sources is improved." Source: https://www.ecdc.europa.eu/sites/default/files/documents/Communicable-disease-threats-report-week-10-2025.pdf Did you know that bacterium "Vibrio cholera (O139)", bacterium "yersinia pestis" and bacterium "shigella disenteriae serotype 1" are mentioned in Table 4 of the WHO's document titled "Pathogens prioritization: a scientific framework for epidemic and pandemic research preparedness"? If you take a look at the rightmost column of the Table 4, you can see that the note "(Pandemic risk)" is mentioned for the following pathogens: - "Vibrio cholera (O139)" (the bacterium that is related to the cholera disease) - "Yersinia pestis" (the bacterium that is related to the plague disease) - "Shigella disenteriae serotype 1" - "Alphavirus venezuelan" Source: See page 12/38 on the following link: https://cdn.who.int/media/docs/default-source/consultation-rdb/prioritization-pathogens-v6final.pdf?sfvrsn=c98effa7_7&download=true Meanwhile, the "scientists" are already talking about the new vaccines for plague, vaccines for Klebsiella pneumoniae, vaccines for Acinetobacter, vaccines for Pseudomonas aeruginosa, vaccines for cholera and vaccines for shigella. See the following articles: 1. "Manganese-Based Nanoparticle Vaccine for Combating Fatal Bacterial Pneumonia" Source: https://pubmed.ncbi.nlm.nih.gov/37784226/ 2. "A single-dose F1-based mRNA-LNP vaccine provides protection against the lethal plague bacterium" Source: https://pubmed.ncbi.nlm.nih.gov/36888708/ 3. "mRNA-LNP vaccines combined with tPA signal sequence elicit strong protective immunity against Klebsiella pneumoniae" Source: https://pubmed.ncbi.nlm.nih.gov/39745376/ 4. Clinical trial NCT04959344 titled "Safety and Immunogenicity of a Klebsiella Pneumoniae Tetravalent Bioconjugate Vaccine (Kleb4V)" Here are two quotes: "Sponsor LimmaTech Biologics AG" "Study Completion (Actual) 2022-09-26" Source: https://clinicaltrials.gov/study/NCT04959344 5. Clinical trial NCT01563263 titled "Confirmatory Phase II/​III Study Assessing Efficacy, Immunogenicity and Safety of IC43" Here are s few quotes: "Sponsor Valneva Austria GmbH" "Official Title A Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43 Recombinant Pseudomonas Vaccine Intensive Care Patients" "Conditions Pseudomonas Aeruginosa Infection" Source: https://clinicaltrials.gov/study/NCT01563263 6. "Self-assembled ferritin nanoparticles displaying PcrV and OprI as an adjuvant-free Pseudomonas aeruginosa vaccine" Source: https://pubmed.ncbi.nlm.nih.gov/37415986/ 7 ."Preparation and evaluation of chitosan nanoparticles containing CtxB antigen against Vibrio cholera" Source: https://pubmed.ncbi.nlm.nih.gov/30138759/ 8. "Nanoparticles-based technologies for cholera detection and therapy" Source: https://pubmed.ncbi.nlm.nih.gov/37925157/ 9. "A multi-epitope protein vaccine encapsulated in alginate nanoparticles as a candidate vaccine against Shigella sonnei" Source: https://pubmed.ncbi.nlm.nih.gov/39341926/ 10. "The Shigella Vaccines Pipeline" Among other vaccines, the following vaccines are mentioned in "Table 3" of that article: - S4V-EPA by LimmaTech - SF2a-TT15 by Pasteur Institute - InvaplexAR-DETOX by WRAIR - altSonflex1-2-3 by GVGH (GSK) Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC9504713/ #amr #antimicrobialresistance #cholera #plague #yersiniapestis #shigella #mrnavaccine #nanotechnology #2025 #europe #eu #africa #germany #ecdc #bacterialpathogen #virus #viralpathogen #pandemicexercise #tabletopexercise #2019 #antibioticvsvaccine